Lay User Evaluation of the Panbio™ HCV Self-Test

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14+
SponsorAbbott Rapid Dx

About this trial

This is a prospective, multi-centre study designed to evaluate the usability of the Panbio™ HCV Self Test, when performed by untrained lay users in an observed study setting. The Panbio™ HCV Self Test detects antibodies to Hepatitis C Virus (HCV). The study validation will be conducted in accordance with the World Health Organisation's technical guidance on Hepatitis C rapid diagnostic tests for professional use and/or self-testing (TSS-16).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant is aged 14 or over

Participant agrees to all aspects of the study and is able and willing to provide informed consent / assent with parental consent.

Disqualifiers

Participant has already participated in this study on a previous occasion.

Participant is aware of their HCV status

Participant is deemed unfit for the study by the Investigator.

Participant has a condition deemed unfit by the Investigator to safely perform or receive the test.

Trial design

Design model

Single group

Treatments tested in this trial

  • Panbio™ HCV Self Test

    Diagnostic test

    Rapid diagnostic test (self-test and professional) plus laboratory reference tests

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Lay user / professional user test result concordance

To assess the concordance between the Panbio™ HCV Self Test, as performed by lay users based on self-collected finger-stick samples, and the Panbio™ HCV Self Test performed by a trained health care worker, who also will collect the finger-stick sample required for the test and perform the test.

Time frame
5 months
2

Lay user / laboratory test result concordance

To establish clinical performance (concordance with the reference test) for the Panbio™ HCV Self Test, as performed by lay users using finger-stick whole blood samples, when compared to reference testing using venous plasma samples.

Time frame
5 months

Secondary outcomes

1

Usability evaluation - lay user experience

To assess the usability of the Panbio™ HCV Self Test, as performed by lay users, based on a participant questionnaire evaluation by the lay user participant. The participant questionnaire includes questions to assess the lay users\' experience when performing the test. Most questions have a Yes / No answer option, with free text possible. Some questions require a free text answer.

Time frame
5 months
2

Usability evaluation - Self-test observer records

To assess the usability of the Panbio™ HCV Self Test, as performed by lay users based on a questionnaire evaluation by the study staff observer. In the observer questionnaire, particular attention will be paid to compliance regarding factors considered critical for the test, such as reading the IFU/ QRG and applying the correct test volume. The observer questionnaire is not reporting scores on a scale, but is recording observations regarding how the users complete each step. For each step, a question is asked whether the user conducted a certain procedure, and a Yes / No answer is requested, with Monitor Notes when applicable.

Time frame
5 months
3

Lay user / professional user results interpretation concordance

To assess the concordance between the self-test results (obtained by the self-tester) when interpreted by the lay user and by the observer.

Time frame
5 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Abbott Rapid Dx

Lead sponsor

Aga Khan University

Collaborator

Clinic 553 Karachi

Collaborator

Ezintsha Clinical Research Center

Collaborator

This trial is not recruiting at the moment. You can still explore other options: